Annexin 2 (ANXA2) plays a critical role in hematopoietic stem cell (HSC) localization to the marrow niche. In part, ANXA2 supports HSCs by serving as an anchor for stromal-derived factor-1 (CXCL12/SDF-1 
Introduction
Prostate cancer is the second leading cause of cancer deaths in American males (1, 2) . The high mortality rate is due mainly to the spread of malignant cells to many tissues including bone (3, 4) . At the single cell level, the multistep process of metastasis is very inefficient, where less than $2% of disseminated tumor cells (DTC) are estimated to form micrometastasis and fewer still ($0.02%) develop into macrometastasis (5) . In part, a barrier for DTCs to form clinically relevant metastases is not only the ability to survive in the circulation during dissemination but also the ability to home to and engage in a safe environment, which can immediately support their survival. We recently reported that DTCs target and engage the hematopoietic stem cell (HSC) niche to establish metastases in marrow (6) . While the nature and the components of the HSC niche remain controversial, significant evidence suggests that cells of the osteoblastic lineage, adipocytes, osteoclasts, osteomacs, and endothelial cells aid in the development and organization of the HSC niche (7) (8) (9) .
Bone marrow stromal cells (BMSC) are a heterogeneous population of cells, which also are known to contribute to the generation of the HSC niche. There is growing evidence that a subpopulation of BMSCs has progenitor and/or stem-like activities that are capable of locally generating multiple connective tissue lineages under conditions of stress or wound repair (e.g., endothelial, adipocytic, osteoblastic, cartilage, and muscle cells; ref. [7] [8] [9] . Although still controversial, if BMSCs are mobilized or injected into the circulation, BMSCs may participate in tissue repair at distant organs (9) . In the context of tumors, when BMSCs are localized in tumor beds, cytokine cross-talk leads to the emergence of an increasingly aggressive tumor phenotype (10) (11) (12) (13) (14) (15) (16) (17) .
Two important signal transducers in the bone marrow niche are stromal-derived factor-1 (SDF-1 or CXCL12; refs. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] and annexin 2 (ANXA2; ref. 30) . CXCL12 is a central regulator of HSC homing and recruitment into marrow and HSC mobilization into the circulation. Indeed, blockage of CXCL12 or its receptor prevents HSC homing or mobilizes niche-bound HSC into the circulation (18) (19) (20) (21) (22) (23) (24) . ANXA2, on the other hand, likely serves as an adhesion molecule, facilitating HSC binding to the osteoblastic niche (25) . Critically, it has been shown that CXCL12 and ANXA2 directly bind to one another, and this interaction facilitates hematopoietic progenitor cell migration in response to CXCL12 (26) . In fact, loss of ANXA2 is associated with decreased levels of CXCL12 in marrow. Likewise, CXCL12 and ANXA2 play similar roles in recruiting and localizing tumor cells into the HSC niche (27) (28) (29) (30) .
In the present study, we explored whether ANXA2 facilitates metastasis and growth of prostate cancer through its interactions with CXCL12. We demonstrate that ANXA2-expressing BMSCs express more CXCL12 than do ANXA2-deficient BMSCs, and the production of these 2 proteins increases the recruitment of prostate cancer cells into the marrow niche. In addition, CXCL12 produced by ANXA2-expressing BMSCs promotes prostate cancer proliferation, protects prostate cancer from chemotherapyinduced apoptosis, and increases the development of vascular structures. Our results suggest that ANXA2 and CXCL12 interactions facilitate the recruitment, growth, and survival of prostate cancer cells in marrow.
Materials and Methods

Cell culture
The human prostate cancer cell line PC3 was obtained from the ATCC. C4-2B, the metastatic subline of the prostate cancer cell line LNCaP, was originally isolated from a lymph node of a patient with disseminated bony and lymph node involvement. Luciferase-expressing prostate cancer cell lines (PC3 Luc and C4-2B 
Quantitative RT-PCR
Total RNA was extracted using the RNeasy mini or micro kit (Qiagen). cDNA was established using a First-Strand synthesis kit (Invitrogen). Quantitative PCR was performed on an ABI 7700 sequence detector (Applied Biosystems) using TaqMan Universal PCR Master Mix Kit (Applied Biosystems) according to the directions of manufacturer. TaqMan MGB probes (Applied Biosystems) were as follows: human Anxa2r (Hs01588662_s1) and human Cxcr4 (Hs00237052_m1). b-Actin (Hs99999903_m1) was used as an internal control for the normalization of target gene expression.
ELISAs
BMSC Anxa2þ/þ or BMSC Anxa2À/À (1 Â 10 5 cells per well) were cultured in 12-well culture plates for 48 hours. An antibody sandwich ELISA was used to evaluate CXCL12 levels in the CM by the modification of directions of manufacturer (R&D Systems). CXCL12 secretion levels were normalized to total cell numbers.
Immunostaining
Cells and tumor sections were used for immunostaining. Cells were fixed with 10% neutral-buffered formalin (cat. HT501320; Sigma) and permeabilized with PBT (1:500 dilution of Triton-X100 in PBS). Tumor sections were deparaffinized, hydrated, and then blocked with Image-iT FX signal enhancer (cat. I36933; Life Technology) for 30 minutes and incubated for 2 hours at room temperature with primary antibodies combined with reagents of Zenon Alexa Fluor 488 (green) or 555 (red) labeling kit (Life Technology). Polyclonal anti-ANXA2 (cat. 610069; 1:25 dilution; BD Pharmingen), polyclonal anti-CXCL12 (cat. ab25117; 1:100 dilution; Abcam), monoclonal anti-HLA (cat. 311402; 1:50 dilution; BioLegend), CD31 (cat. ab32457; 1:100 dilution; Abcam), monoclonal p-AKT (cat. ab81283; 1:100 dilution; Abcam), and monoclonal anti-AKT (cat. ab32505; 1:100 dilution; Abcam) were used as primary antibodies. After washing with PBS, tumor sections were mounted with ProLong Gold antifade reagent with DAPI (cat. P36931; Invitrogen). Images were taken with Olympus FV-500 confocal microscope. In some cases, the tumor sections were stained by TUNEL staining (cat. 11684817910; Roche).
Western blotting
PC3 cells (89%-90% confluent) were cultured in 6-well plates in RPMI (1 mL) without FBS for 18 hours. After serum starvation, the cells were treated with ANXA2 (1 mg/mL), CXCL12 (200 ng/mL), or a combination of ANXA2 (1 mg/mL) and CXCL12 (200 ng/mL) for 30 minutes at 37
C. Whole-cell lysates were prepared from cells, separated on 10% SDS-PAGE, and transferred to polyvinylidene difluoride (PVDF) membranes. The membranes were first incubated with 5% milk for 1 hour before the addition of antibodies to p-AKT (cat. 9271; 1:1,000 dilution; Cell Signaling) and AKT (cat. 9272; 1:1,000 dilution; Cell Signaling) followed by overnight at 4 C. Subsequently the blots were incubated with peroxidase-coupled anti-rabbit IgG secondary antibody (cat. 7074; 1:2,000 dilution; Cell Signaling) for 1 hour, and protein expression was detected with SuperSignal West Dura Chemiluminescent Substrate (cat. Prod 34075; Thermo Scientific).
Subcutaneous tumor growth
To evaluate tumor growth, subcutaneous tumors were established. The PC3 luc cells (2 Â 10 5 cells) mixed with BMSC Anxa2þ/þ or BMSC Anxa2À/À (2 Â 10 5 cells) in Collagen I (cat. 354236; BD Bioscience) were injected subcutaneously into 5-to 7-week-old male SCID mice. Mice were imaged weekly by bioluminescence imaging (BLI). After 5 weeks, the animals were sacrificed and tumors were prepared for histology.
Intratibial tumor growth
To evaluate tumor growth in bone marrow, PC3 luc (1 Â 10 5 cells) or C4-2B luc (3 Â 10 5 cells) were inoculated intratibially into 5-to 7-week-old male SCID mice. For intratibial injection, mice were anesthetized with 2.5% isofluorane/air, and both legs were cleaned with betadine and 70% ethanol. The knee was flexed and a 27-G3/8-inch needle was inserted into the proximal end of right tibia followed by injection of 20 mL single-cell suspensions of prostate cancer cells. Tumors were allowed to become established for 5 weeks.
All animals were sacrificed at week 5 and tibiae with tumors were collected for histology.
Statistical analyses
Results are presented as mean AE SD. Significance of the difference between 2 measurements was determined by unpaired Student t test, and multiple comparisons were evaluated by the Newman-Keuls multiple comparison test. Values of P < 0.05 were considered significant.
Results
ANXA2 and CXCL12 expression are correlated in the bone marrow environment
We examined the extent to which ANXA2 expression is correlated with CXCL12 expression in the long bones of wild-type and Anxa2 knocked-out mice. CXCL12 expression was robustly expressed in marrow of wild-type mice compared with ANXA2-deficient mice (Fig. 1A) . In vitro, more CXCL12-expressing cells were identified in BMSCs derived from wildtype mice (BMSC Interactions between ANXA2 and CXCL12 by BMSCs contribute to prostate cancer cell adhesion and migration To test whether expression of the ANXA2 receptor (Anxa2r) and the receptor for CXCL12, Cxcr4, are correlated, mRNA levels were quantified using qRT-PCR. Significantly higher levels of Anxa2r or Cxcr4 expression were observed in the bone-homing prostate cancer cell lines PC3 and C4-2B, compared with human BMSCs ( Fig. 2A and B ). Studies were next performed to determine whether ANXA2 serves as an adhesion molecule for prostate cancer cell binding to BMSCs. As shown in Fig. 2C . When the experiments were repeated in the presence of a function blocking antibody targeting ANXA2, significant reduction of prostate cancer binding to BMSC Anxa2þ/þ were observed (Fig. 2D) .
CXCL12 is a key regulator of hematopoietic stem cell migration and tumor metastasis into the marrow. As ANXA2 expression is linked to expression of CXCL12, we next performed migration assays of prostate cancer cells in response to BMSC Anxa2þ/þ or BMSC Anxa2À/À . For these studies, prostate cancer cells were added to the upper chamber of a migration assay dish and CM derived from BMSC Anxa2þ/þ or BMSC Anxa2À/À was added to the bottom chambers. More prostate cancer cells migrated toward the CM derived from BMSC Anxa2þ/þ than they did toward BMSC Anxa2À/À CM (Fig. 2E) . When the experiments were performed in the presence of neutralizing anti-CXCL12 antibody or AMD3100, a selective CXCR4 antagonist, significant reduction of prostate cancer migrating to BMSC Anxa2þ/þ CM were observed (Fig. 2F ). These data suggest that prostate cancer moves toward CXCL12 secreted by BMSCs. These observations suggest that ANXA2 and CXCL12 participate in tissue localization of prostate cancer. (Fig. 3A) .
On the basis of the in vitro studies, we examined whether there are differences in the ability of BMSCs to support prostate cancer growth in vivo linked to expression of ANXA2 and CXCL12. For these studies, tumors were established by subcutaneously injecting PC3
Luc cells ( (Fig. 3D) .
To explore the molecular mechanisms whereby ANXA2 and CXCL12 regulate tumor growth, we examined whether ANXA2 alone, CXCL12 alone, or the combination of ANXA2 and CXCL12 activates AKT in prostate cancer cells. For these investigations, prostate cancer cells were treated with ANXA2 and/or CXCL12 and phosphorylation of AKT was evaluated by Western blotting. The data demonstrate that ANXA2 or CXCL12 alone highly induces AKT phosphorylation in PC3 cells, and the combination of ANXA2 and CXCL12 significantly enhances activation of AKT phosphorylation (Fig. 3E) . To validate the in vitro results, we examined induction of AKT phosphorylation on the tumors generated in Fig. 3B . The immunofluorescence data demonstrate that the expression levels of p-AKT was significantly enhanced in the tumor cells mixed with BMSC Anxa2þ/þ compared with tumors established with BMSC Anxa2À/À or tumors alone (Fig. 3F ). These data suggested that ANXA2 and CXCL12 facilitate prostate cancer growth via the AKT pathway.
Expression of ANXA2 and CXCL12 by BMSCs contributes to protection from chemotherapy-induced apoptosis Prostate cancer cells are known to develop resistance to chemotherapies, particularly in marrow. To explore the role that ANXA2 and CXCL12 play in this process, cocultures of BMSCs and prostate cancer cells were evaluated by FACS for Annexin V staining (Fig. 4) . Apoptotic levels for prostate cancer cells cocultured with BMSC Anxa2þ/þ were lower than when prostate cancer cells were cultured alone or with BMSC Anxa2À/À
. Further protection from apoptosis was noted when the microtubule-inhibiting drug taxotere was included in the cultures (Fig. 4A and B) . To evaluate whether these in vitro studies are also relevant to our in vivo studies, TUNEL staining was next performed on the tumors generated in Fig. 3B . Fewer apoptotic tumor cells were found in the tumors established with PC3
Luc and BMSC Anxa2þ/þ compared Fig. 4C and D) . Together the data suggest that ANXA2 and CXCL12 expression by BMSCs are likely to play a role in the resistance of prostate cancer cells to chemotherapy.
Expression of ANXA2 and CXCL12 by BMSCs contributes to the generation of vascular structures in tumors
To determine whether ANXA2 and CXCL12 contribute to endothelial cell recruitment into tumor beds, migration by endothelial cells in response to CM isolated from BMSCs was evaluated. When HBMEC were added to the upper chamber of the culture dish with BMSCs cell CM present in the bottom, fewer HBMEC migrated toward BMSC Anxa2À/À CM compared with BMSC Anxa2þ/þ CM. When the experiments were performed in the presence of AMD3100, significant reduction of HBMECs migrating to BMSC Anxa2þ/þ or BMSC Anxa2À/À CM was observed (Fig. 5A ).
These data suggest that endothelial cells move toward CXCL12 secreted by ANXA2 expressing BMSCs and further suggest that ANXA2 and CXCL12 participate in tissue localization of endothelial cells. Next, immunostaining for CD31, a marker of endothelial cells, was performed on tumors generated by PC3 cells in combination with BMSC Anxa2þ/þ or BMSC Anxa2À/À . Tumors established with PC3
Luc and BMSC Anxa2þ/þ demonstrated significantly larger and more abundant CD31-expressing blood vessels compare the tumors established with PC3 and BMSC Anxa2À/À (Fig. 5B  and C) .
One possible mechanism that may account for the observation that more CD31 endothelial cells were present in tumors generated with BMSC Anxa2þ/þ is that BMSCs enhance endothelial cell survival. To test this possibility, endothelial cells were treated with ANXA2 and CXCL12 alone or in combination, and survival was determined by FACS for Annexin V staining as a measurement of apoptosis. We found that fewer HBMECs underwent apoptosis in the presence of ANXA2 and/or CXCL12 (Fig. 5D) (Fig. 5E and F) . Together the data suggest that ANXA2-mediated CXCL12 in BMSCS plays an important role in sustaining vascular structures.
Discussion
Recent studies suggest that niche cells in the bone marrow participate in the cellular and molecular events for the tumor progression and metastasis (5) (6) (7) (8) (9) . In this study, we show ANXA2 and CXCL12 interactions produced by BMSCs facilitate prostate cancer recruitment and proliferation, aid in protection Together these data suggest that ANXA2 and CXCL12 interactions may be integral to tumor development in the marrow microenvironment.
The engagement of DTCs to the bone marrow niche and the maintenance of these cells in the niche are essential steps to establish metastases. In this context, ANXA2, an osteoblastexpressed adhesion molecule, may be a crucial docking signal (30) . CXCL12 is a chemokine, which in addition to functioning as a secreted molecule is known to bind to extracellular matrix proteins (27) (28) (29) . Previously, we and other groups have identified several factors that may be involved in establishing a tumor niche. We have shown that CXCL12 produced by the niche participates in the regulation of prostate cancer metastasis (27) (28) (29) , and we have also demonstrated that ANXA2 and its receptor ANXA2R regulate the localization and maintenance of prostate cancer cells in the niche (30) . More importantly, tumor cell metastases share molecular mechanisms that regulate HSC homing and localization to the bone marrow (27) (28) (29) (30) . Subsequently, we reported that ANXA2 and CXCL12 bind directly to each other, and these interactions facilitate hematopoietic progenitor cell migration in response to CXCL12 (26) . We therefore hypothesized that ANXA2-expressing bone marrow stromal cells facilitate prostate cancer metastasis and growth by inducing CXCL12. We found that ANXA2-expressing BMSCs express elevated levels of CXCL12, which increases the binding and recruitment of prostate cancer cells into the marrow niche and promotes prostate cancer proliferation. Thus, a model can be envisioned in which CXCL12 facilitates the recruitment of DTCs to the niche, ANXA2 facilitates prostate cancer engagement into the niche, whereupon CXCL12 produced by the niche cells stimulates prostate cancer growth. CXCL12 is known to play a central role in promoting the growth of tumor cells including ovarian carcinoma (33) , small cell lung cancer (34), head and neck squamous cell carcinoma (35) , pancreatic cancer (36) , and prostate cancer (37) . It has also been demonstrated that secreted CXCL12 induces prostate cancer proliferation in in vitro (37) (38) (39) , following activation of ERK1/2 and AKT pathways (34, 36, 37) . We also found that ANXA2 and CXCL12 interactions effectively activate through AKT signaling pathways that, in many respects, have been linked to tumor growth.
In marrow, osteoblasts play important roles in the production of a mineralized matrix that serves as the basis of bone remodeling. Osteoblasts are also known to express many cell adhesion molecules, including ANXA2, which may facilitate bone activities. Recently, it was demonstrated that ANXA2 regulates osteogenic differentiation, yet the molecular mechanisms remain unclear (40) (41) (42) . Hypoxia and VEGF both induce ANXA2 expression by osteoblasts and endothelial cells through SRC and MEK kinase-dependent pathway (40) . ANXA2 increases the mineralization of osteoblastic cells and alkaline phosphatase activity (41) . ANXA2 also supports osteogenic differentiation of mesenchymal stem cells (MSC) and further regulates both intramembrane and endochondral ossification in adolescent idiopathic scoliosis (AIS; ref. 42) . We have also reported that fewer osteoblasts are found in the long bone of Anxa2 knocked-out (Anxa2 À/À ) mice compared with wild-type (Anxa2
) mice and, likewise, a decrease of bone phenotype markers (Runx2, osteocalcin, Collagen 1a) is seen in bones from these knock-out mice (data not shown). Critical to this report, lower CXCL12-expressing cells in BMSCs derived from Anxa2 knocked-out mice (BMSC Anxa2À/À ) were identified compared with cells isolated from wild-type mice (BMSC Anxa2þ/þ ). As ANXA2 mediates osteogenic activities in marrow, the release of tumor-supporting activities from either osteoblasts or bone matrix may provide some clues to how ANXA2 regulates metastasis and CXCL12 signaling simply by providing lower levels of substrates or adhesive surfaces for DTCs to lodge. Alternatively, while the molecular mechanisms need to be further investigated, our data also suggest that an ANXA2-deficient environment may lead to less osteoblastic regulation of bone remodeling, which ultimately results in a decrease of prostate cancer tumor growth and survival in bone marrow. Both of these possibilities are worthy of further study. CXCL12 is known to regulate tumor cell apoptosis. CXCL12 may protect tumor cells from drug-induced apoptosis directly through the activation of antiapoptotic pathways but also indirectly by modulating the adherence of cancer cells. CXCL12 mediates adhesion of small cell lung cancer cells (SCLC) to marrow stromal cells and protects SCLC against drug-induced apoptosis (34) . CXCL12 activates NF-kB, which inhibits radiation-induced TNFa production and tumor apoptosis (43, 44) . Moreover, NF-kB signaling is involved in the expression of CXCR4, thus promoting tumor cell migration and metastasis (43) (44) (45) . In this study, we found that more prostate cancer cells survived when cocultured with BMSC Anxa2þ/þ vs. coculture with BMSC Anxa2À/À in in vitro. Similar results were obtained in in vivo studies, as fewer apoptotic cells were found in tumors established with BMSC Anxa2þ/þ versus those with BMSC Anxa2À/À cells. In part, these results may be due to regulation of CXCL12 expression by ANXA2 or enhanced ability to localize CXCL12 to cell surfaces, which may be more efficient in activating cell functions than in a soluble form. Whether either of these 2 possibilities is responsible for how ANXA2 interacts with CXCL12 remains unclear and will require additional investigation.
Finally, migration, expansion, and survival of vascular endothelial cells are essential for establishment of a functional network of angiogenesis. Ling and colleagues demonstrated that Anxa2-deficient mice have markedly impaired neoangiogenesis. This contributes to a failure to localize plasmin activity to the endothelial cell surface and a failure to activate selected matrix metalloproteinase (32) . It has also been demonstrated that ANXA2-dependent plasmin generation in breast tumor is necessary to trigger the switch to neoangiogenesis, thereby stimulating tumor growth (46, 47) . We found that PC3
Luc cells implanted with BMSC Anxa2þ/þ showed significantly more and larger CD31-expressing blood vessels than PC3 Luc mixed BMSC Anxa2À/À cells. It has also been demonstrated that CXCL12 stimulates the formation of capillarylike structures with human vascular endothelial cells (48) (49) (50) (51) . Recently, we demonstrated that prostate cancer cells use CXCL12 and its receptors (CXCR4 and CXCR7) as key elements in metastasis and growth in bone, where CXCR4 signaling leads to an angiogenic switch (48) (49) (50) . We have further demonstrated that CXCR4 signaling results in the activation of MAP and AKT pathways, which ultimately increases the secretion of VEGF and IL8 (48) (49) (50) . More importantly, CXCR4 directly regulates blood vessel formation (48), due to inhibiting the secretion of the vascular inhibitor phophoglycerate kinase 1 (PGK1; ref. 50). Thus, there are both direct and indirect mechanisms whereby ANXA2 and CXCL12 interactions may regulate tumor growth. Clearly, more studies are warranted. In summary, this work provides further evidence for the roles that ANXA2 and CXCL12 play in the tumor microenvironment and specifically in prostate cancer migration, growth, and survival in bone marrow. Our data also provide evidence that ANXA2 and CXCL12 regulate vascular formation in tumors. Together these studies suggest that ANXA2 and CXCL12 interactions facilitate a number of activities critical for tumor growth. 
